Back to search

Canada· CA-DIN-00022381

CORTROSYN INJ 0.25MG

A tetracosactide product containing tetracosactide, registered in Canada by AMPHASTAR PHARMACEUTICALS, INC.. The same ATC class is registered in 10 of our 19 countries.

ATC H01AA02

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedCORTROSYN INJ 0.25MGATCH01AA02REGISTER NO.CA-DIN-00022381PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Tetracosactide is registered in 10 of 19 countries.

Countries holding a registration under ATC H01AA02 (tetracosactide), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 5 of them publish a price we can compare per daily dose

Tetracosactide · ATC H01AA02

10 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
TETRACOSACTIDE
Manufacturer
AMPHASTAR PHARMACEUTICALS, INC.
Country
Canada (CA)
ATC code
H01AA02
ATC class
Tetracosactide
Defined daily dose
0.25 mg, P
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

295 interactions on record for tetracosactide.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tetracosactide · interactions on record

295 records

  • 29 severe
  • 246 moderate
  • 20 minor

Most severe, free to view

  • DesirudinB01AE01severe
  • Magnesium hydroxideA02AA04moderate
  • Kombinationen von AluminiumsalzenA02AB10moderate
  • Liquid paraffinA06AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tetracosactide in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tetracosactide products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Austria · Synacthen Ampulle, Synacthen Depot
  • Belgium · Synacthen, Synacthen Depot
  • Denmark · Synacthen
  • France · Synacthene, Synacthene Retard
  • Ireland · Synacthen
  • Italy · Synacthen
  • Luxembourg · Synacthen, Synacthen Dépôt
  • Netherlands · Synacthen
  • Sweden · Synacthen, Synacthen Depot

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dd5f0520-aef6-43e1-9adc-19118cbfb46a
GET /v1/drugs/dd5f0520-aef6-43e1-9adc-19118cbfb46a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "00022381",
  "form": "POWDER FOR SOLUTION",
  "class": "Human",
  "routes": [
    "INTRAVENOUS",
    "INTRAMUSCULAR"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "H01AA02",
  "schedule": [
    "Prescription"
  ],
  "drug_code": "1954",
  "strengths": [
    "0.25 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "TETRACOSACTIDE"
  ],
  "product_categorization": null
}

See everything about tetracosactide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.